BTTX's Business Model
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.bettertx.com |
| CEO (Chief Executive Officer) | David P. Perry |
| Number of Employees | |
| IPO date | March 17, 2021 |
BTTX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 548 Market Street |
| City | San Francisco |
| State | CA |
| Phone | 415 887 2311 |
| Zip Code | 94104 |
| Other Identifiers | |
| CIK | 0001832415 |
| ISIN | US08773T1043 |
| CUSIP | 08773T104 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Volume | 172 |
| Average Volume | 11.8 Thou. |
| Day’s Range | 0.0001 – 0.0001 |
| 52 Week Range | 0.0001-0.016 |
| MA (50) | 0.000128 |
| MA (200) | 0.0001615 |
| Market Cap | 5.45 Thou. |
| Shares Out. | 54.52 Mil. |
| Earnings Date | Jul 21, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
